• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Diabetes Metab Syndr Obes . Increased Insulin Requirements in Severe Cases of Covid-19 are Higher Than in Moderate Cases

tetano

Editor, Senior Moderator
Diabetes Metab Syndr Obes


. 2024 Oct 10:17:3727-3733.
doi: 10.2147/DMSO.S480598. eCollection 2024. Increased Insulin Requirements in Severe Cases of Covid-19 are Higher Than in Moderate Cases

Takaaki Matsui[SUP] 1 [/SUP], Emi Ushigome[SUP] 1 [/SUP], Masahide Hamaguchi[SUP] 1 [/SUP], Kazuki Sudo[SUP] 2 [/SUP], Nobuko Kitagawa[SUP] 1 [/SUP], Yuriko Kondo[SUP] 1 [/SUP], Yuka Hasegawa[SUP] 1 [/SUP], Dan Imai[SUP] 1 [/SUP], Tomohiro Hattori[SUP] 1 [/SUP], Masahiro Yamazaki[SUP] 1 [/SUP], Teiji Sawa[SUP] 2 [/SUP], Michiaki Fukui[SUP] 1 [/SUP]



Affiliations
Abstract

Purpose: Despite the low overall death rate of coronavirus disease 2019 (COVID-19), no study has examined the association between COVID-19 severity and the total daily insulin dose required for glycemic control. The aim of this study was to determine the maximum total daily insulin dose required according to COVID-19 severity, and the number of days required to reach the maximum insulin dose in patients with COVID-19 who used insulin during hospitalization.
Patients and methods: This retrospective cohort study included participants aged 20-90 years with a confirmed diagnosis of COVID-19 who used insulin during hospitalization at Kyoto Prefectural University of Medicine Hospital between March 4, 2020, and May 31, 2021. Factors associated with maximum insulin dose during hospitalization were evaluated using linear regression analyses.
Results: The maximum insulin doses were 31.8, 76.8, and 230.7 U/day, and the numbers of days between COVID-19 diagnosis and the need for maximum insulin were 15.6, 17.1, and 13.7 days in patients without ventilator management, with ventilator management, and with ventilator and extracorporeal membrane oxygenation management, respectively. Multivariate linear regression analyses revealed that hemoglobin A1c level (β = 15.87, P = 0.001), use of a ventilator (β = 50.53, P < 0.001), and use of extracorporeal membrane oxygenation (β = 150.36, P < 0.001) were independent determinants of maximum insulin dose.
Conclusion: Patients with severe COVID-19 required a significantly higher maximum insulin dose than did those with moderate COVID-19. The maximum insulin dose was reached approximately 2 weeks after onset. Furthermore, the hemoglobin A1c level on admission and the use of a ventilator or extracorporeal membrane oxygenation during hospitalization were associated with the need for maximum insulin dose.

Keywords: COVID-related diabetes; SARS-CoV-2; glycemic control; insulin resistance; retrospective cohort study.

 
Back
Top Bottom